Frauenheilkunde up2date, Table of Contents Frauenheilkunde up2date 2011; 5(06): 381-399DOI: 10.1055/s-0031-1283786 Gynäkologische Endokrinologie und Reproduktionsmedizin © Georg Thieme Verlag KG Stuttgart · New YorkHabituelle Aborte B. HinneyRecommend Article Abstract Buy Article All articles of this category Full Text References Literatur 1 Nybo AndersenAM, Wohlfahrt J, Christens P et al. Maternal age and fetal loss: population based register linkage study. Br Med J 2000; 320: 1708-1712 2 Franssen MTM, Musters AM, van der Veen F et al. Reproductive outcome after PGD in couples with recurrent miscarriage carrying a structural chromosome abnormality: a systematic review. Hum Reprod Update 2011; 17: 467-475 3 The Practice Committee of the Society for Assisted Reproductive Technology and the Practice Committee of the American Society of Reproductive Medicine. Preimplantation genetic testing: a Practice Committee opinion. Fertil Steril 2008; 90: 136-146 4 Musters AM, Repping S, Korevaar JC et al. Pregnancy outcome after preimplantation genetic screening or natural conception in couples with unexplained recurrent miscarriage: a systematic review of the best available evidence. Fertil Steril 2011; 95: 2153-2157 5 Grimbizis GF, Camus M, Tarlatzis BC et al. Clinical implications of uterine malformations and hysteroscopic treatment results. Hum Reprod Update 2001; 7: 161-174 6 Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril 2009; 91: 1215-1223 7 Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev; 2008 CD003511 8 Coomarasamy A, Truchanowicz EG, Rai R. Does first trimester progesterone prophylaxis increase the live birth rate in women with unexplained recurrent miscarriages?. Br Med J 2011; 342: d1914-d1914 9 Negro R, Schwartz A, Gismondi R et al. Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy. J Clin Endocrinol Metab 2010; 95: e44-e48 10 Maconochie N, Doyle P, Prior S et al. Risk factors for first trimester miscarriage — results from a UK-population-based case-control study. Br J Obstet Gynaecol 2007; 114: 170-186 11 Rumbold A, Middleton P, Pan N, Crowther CA. Vitamin supplementation for preventing miscarriage (Review). Cochrane Database Syst Rev; 2011 CD004073 12 Rai R, Backos M, Elgaddal S et al. Factor V Leiden and recurrent miscarriage – prospective outcome of untreated pregnancies. Hum Reprod 2002; 17: 442-445 13 Robertson L, Wu O, Langhorne P et al. Thrombophilia in pregnancy. A systematic review. Br J Haematol 2006; 132: 171-196 14 Jivraj S, Rai R, Underwood J et al. Genetic thrombophilic mutations among couples with recurrent miscarriage. Hum Reprod 2006; 21: 1161-1165 15 Jivraj S, Makris M, Saravelos S et al. Pregnancy outcome in women with Factor V Leiden and recurrent miscarriage. Br J Obstet Gynaecol 2009; 116: 995-998 16 Gris JC, Mercier E, Quere I et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695-3699 17 Laskin CA, Spitzer KA, Clark CA et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009; 36: 279-287 18 Kaandorp SP, Goddijn M, van der Post JA et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med 2010; 362: 1586-1596 19 Clark P, Walker ID, Langhorne P et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 2010; 115: 4162-4167 20 Dolitzky M, Inbal A, Segal Y et al. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 2006; 86: 362-366 21 Fawzy M, Shokeir T, El TatongyM et al. Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. Arch Gynecol Obstet 2008; 278: 33-38 22 Kaandorp S, Di Nisio M, Goddijn M et al. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome (Review). Cochrane Database Syst Rev; 2009 1. CD004734 23 Branch W. Report of the Obstetric APS Task Force: 13th International Congress on Antiphospholipid Antibodies, 13th April 2010. Lupus 2011; 20: 158-164 24 Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy. A randomized, controlled trial of treatment. Obstet Gynecol 2002; 100: 408-413 25 Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306 26 Porter TF, LaCoursiere Y, Scott JR. Immunotherapy for recurrent miscarriage (Review). Cochrane Database Syst Rev; 2006 2. CD000112 27 Guerin LR, Prins JR, Robertson SA. Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment?. Hum Reprod Update 2009; 15: 517-535 28 Nielsen HS. Secondary recurrent miscarriage and H-Y immunity. Hum Reprod Update 2011; 17: 558-574 29 Jaslow CR, Carney JL, Kutteh WH. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil Steril 2010; 93: 1234-1243 30 Clifford K, Rai R, Regan L. Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Hum Reprod 1997; 12: 387-389 31 Stray-Pedersen B, Stray-Pedersen S. Etiologic factors and subsequent reproductive performance in 195 couples with a prior history of habitual abortion. Am J Obstet Gynecol 1984; 148: 140-146
